These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12071334)

  • 1. Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients.
    Kondo T; Tokinaga N; Suzuki A; Ono S; Yabe H; Kaneko S; Hirano T
    Pharmacol Toxicol; 2002 Mar; 90(3):135-8. PubMed ID: 12071334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study.
    Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T
    Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of slow-release preparations of sodium valproate.
    Yamatogi Y; Yoshinaga H; Oka E; Ohtahara S; Yamashita S; Furuno K; Gomita Y
    Psychiatry Clin Neurosci; 1995 Dec; 49(5-6):309-10. PubMed ID: 8726120
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate.
    Genton P
    Acta Neurol Scand Suppl; 2005; 182():26-32. PubMed ID: 16359430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.
    Herranz JL; Arteaga R; Adín J; Armijo JA
    Eur J Clin Pharmacol; 2006 Oct; 62(10):805-15. PubMed ID: 16896786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Valproate sustained release in the treatment of epilepsy].
    Stefan H; Fraunberger B
    Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
    Stockis A; Sargentini-Maier ML; Brodie MJ
    Epilepsy Res; 2016 Dec; 128():163-168. PubMed ID: 27842261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances.
    Brouwer OF; Pieters MS; Edelbroek PM; Bakker AM; van Geel AA; Stijnen T; Jennekens-Schinkel A; Lanser JB; Peters AC
    Epilepsy Res; 1992 Dec; 13(3):245-53. PubMed ID: 1493787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.
    Wangemann M; Retzow A; Mazur D; Vens-Cappell B
    Int J Clin Pharmacol Ther; 2000 Aug; 38(8):395-401. PubMed ID: 10984013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
    Retzow A; Vens-Cappell B; Wangemann M
    Arzneimittelforschung; 1997 Dec; 47(12):1347-50. PubMed ID: 9450162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach.
    Huo T; Chen X; Lu X; Qu L; Liu Y; Cai S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Oct; 969():109-16. PubMed ID: 25168794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between valproate formulation and phenytoin concentrations.
    Suzuki Y; Nagai T; Mano T; Arai H; Kodaka R; Matsuoka T; Itagaki Y; Ono J; Okada S
    Eur J Clin Pharmacol; 1995; 48(1):61-3. PubMed ID: 7621850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic modelling of valproate in epileptic patients].
    Jakovljević MB; Janković SM; Todorović N; Milovanović JR; Janković S
    Med Pregl; 2010; 63(5-6):349-55. PubMed ID: 21186545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, co-medication, and the presence of spina bifida.
    Omtzigt JG; Nau H; Los FJ; Pijpers L; Lindhout D
    Eur J Clin Pharmacol; 1992; 43(4):381-8. PubMed ID: 1451717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing individual metabolite patterns for patients on valproate therapy.
    Kreher U; Darius J; Wien F
    Eur J Drug Metab Pharmacokinet; 2001; 26(1-2):99-107. PubMed ID: 11554442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of valproate level in human plasma, cerebrospinal fluid and brain tissue following administration of various preparations of valproate and valpromide].
    Wieser HG
    Praxis (Bern 1994); 1994 Oct; 83(40):1111-6. PubMed ID: 7939081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.